A 20-year perspective on the International Fanconi Anemia Registry (IFAR).

Fanconi anemia (FA) is an autosomal recessive disorder characterized by cellular hypersensitivity to DNA cross-linking agents and cancer predisposition. Recent evidence for the interactions of ataxia-telangiectasia mutated protein ATM and breast cancer susceptibility proteins BRCA1 and BRCA2 (identified as FANCD1) with other known FA proteins suggests that FA proteins have a significant role in DNA repair/recombination and cell cycle control. The International Fanconi Anemia Registry (IFAR), a prospectively collected database of FA patients, allows us the unique opportunity to analyze the natural history of this rare, clinically heterogeneous disorder in a large number of patients. Of the 754 subjects in this study, 601 (80%) experienced the onset of bone marrow failure (BMF), and 173 (23%) had a total of 199 neoplasms. Of these neoplasms, 120 (60%) were hematologic and 79 (40%) were nonhematologic. The risk of developing BMF and hematologic and nonhematologic neoplasms increased with advancing age with a 90%, 33%, and 28% cumulative incidence, respectively, by 40 years of age. Univariate analysis revealed a significantly earlier onset of BMF and poorer survival for complementation group C compared with groups A and G; however, there was no significant difference in the time to hematologic or nonhematologic neoplasm development between these groups. Multivariate analysis of overall survival time shows that FANCC mutations (P =.007) and hematopoietic stem cell transplantation (P = <.0001) define a poor-risk subgroup. The results of this study of patients registered in the IFAR over a 20-year period provide information that will enable better prediction of outcome and aid clinicians with decisions regarding major therapeutic modalities.

[1]  Hans Joenje,et al.  The emerging genetic and molecular basis of Fanconi anaemia , 2001, Nature Reviews Genetics.

[2]  Hans Joenje,et al.  Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA , 1996, Nature Genetics.

[3]  C. Mathew,et al.  Positional cloning of the Fanconi anaemia group A gene , 1996, Nature Genetics.

[4]  C. Mathew,et al.  Complementation analysis in Fanconi anemia: assignment of the reference FA-H patient to group A. , 2000, American journal of human genetics.

[5]  J. Greenbaum,et al.  Spectrum of sequence variation in the FANCG gene: An International Fanconi Anemia Registry (IFAR) study , 2003, Human mutation.

[6]  S. Batish,et al.  Evaluation of Growth and Hormonal Status in Patients Referred to the International Fanconi Anemia Registry , 2001, Pediatrics.

[7]  S. Ganesan,et al.  Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. , 2001, Molecular cell.

[8]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[9]  S. Batish,et al.  Spectrum of sequence variations in the FANCA gene: An International Fanconi Anemia Registry (IFAR) study , 2003, Human mutation.

[10]  A. Rogatko,et al.  International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. , 1989, Blood.

[11]  W. R. Hart,et al.  Multiple squamous‐cell carcinomas in fanconi's anemia , 1982, Cancer.

[12]  R. G. Allen,et al.  Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry. , 1991, Cancer genetics and cytogenetics.

[13]  Bo Xu,et al.  Convergence of the Fanconi Anemia and Ataxia Telangiectasia Signaling Pathways , 2002, Cell.

[14]  E L Kaplan.  NON-PARAMETRIC ESTIMATION FROM INCOMPLETE OBSERVATION , 1958 .

[15]  Q. Waisfisz,et al.  The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. , 2000, Human molecular genetics.

[16]  M. Swift,et al.  Reassessment of cancer predisposition of Fanconi anemia heterozygotes. , 1980, Journal of the National Cancer Institute.

[17]  A D Auerbach,et al.  Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study. , 1997, Blood.

[18]  W. R. Shannon,et al.  Cloning of cDNAs for Fanconi's anaemia by functional complementation , 1992, Nature.

[19]  D. Näf,et al.  The Fanconi anaemia proteins, FAA and FAC interact to form a nuclear complex , 1997, Nature Genetics.

[20]  N. Dracopoli,et al.  Current protocols in human genetics , 1994 .

[21]  R. Gale,et al.  Hematologic Abnormalities in Fanconi Anemia: An International Fanconi Anemia Registry Study , 1994 .

[22]  C G Mathew,et al.  Isolation of a cDNA representing the Fanconi anemia complementation group E gene. , 2000, American journal of human genetics.

[23]  A. D’Andrea,et al.  The fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex. , 2000, Blood.

[24]  B. Alter,et al.  Fanconi anemia: myelodysplasia as a predictor of outcome. , 2000, Cancer genetics and cytogenetics.

[25]  B. Alter.  Fanconi's anemia and malignancies , 1996, American journal of hematology.

[26]  Hans Joenje,et al.  The Fanconi anaemia group G gene FANCG is identical with XRCC9 , 1998, Nature Genetics.

[27]  J. Shah,et al.  High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. , 2003, Archives of otolaryngology--head & neck surgery.

[28]  P. Giampietro,et al.  The need for more accurate and timely diagnosis in Fanconi anemia: a report from the International Fanconi Anemia Registry. , 1993, Pediatrics.

[29]  P. Giampietro,et al.  Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study. , 1997, American journal of medical genetics.

[30]  F. Oski,et al.  Hematology of Infancy and Childhood , 1974 .

[31]  G. Draper,et al.  Incidence of second primary tumours among childhood cancer survivors. , 1987, British Journal of Cancer.

[32]  C. Mathew,et al.  Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3 , 1999, British Journal of Cancer.

[33]  David A. Williams,et al.  Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. , 2002, Experimental hematology.

[34]  Hans Joenje,et al.  The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM , 2000, Nature Genetics.

[35]  M. Buchwald,et al.  Evidence for at least four Fanconi anaemia genes including FACC on chromosome 9 , 1992, Nature Genetics.

[36]  K. Kinzler,et al.  The Genetic Basis of Human Cancer , 1997 .

[37]  A. D’Andrea,et al.  Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells. , 2001, Experimental hematology.

[38]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[39]  R. Moses,et al.  Positional cloning of a novel Fanconi anemia gene, FANCD2. , 2001, Molecular cell.

[40]  Hans Joenje,et al.  Biallelic Inactivation of BRCA2 in Fanconi Anemia , 2002, Science.

[41]  H. Deeg,et al.  Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. , 1996, Blood.

[42]  B. Alter.  Bone marrow failure syndromes. , 1991, Clinics in laboratory medicine.

[43]  A. Auerbach,et al.  Carrier frequency of the IVS4 + 4 A-->T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population. , 1995, Blood.

[44]  A. Neder,et al.  Head and neck carcinoma in Fanconi's anaemia--report of a case and review of the literature. , 1995, European journal of cancer. Part B, Oral oncology.